Mitsubishi Tanabe Pharma acquires NeuroDerm for $1bn
Mitsubishi Tanabe Pharma Corp. is acquiring public Israeli biotech NeuroDerm Ltd. (reformulates CNS disorder therapeutics as drug/device combinations for infusion) for $39 in cash per share (a 28% premium), for an equity value of $1bn.
- Controlled Release
- Drug Delivery
- Infusion Therapy Equipment and Supplies
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.